Multiple Myeloma
Commentary
‘Less is More’ in Myeloma
A young hematologist shares insights gleaned from studying the history of clinical trials.
Conference Coverage
MM:New Tool Gauges Post–CAR T Relapse Risk
Key disease, treatment, and inflammation risk factors predict patients at a higher risk of relapse.
Feature
FDA Withdraws Melflufen Approval, but EMA Still Allows Its Use
In the FDA’s first use of its expedited withdrawal process, the agency removes Pepaxto from the US market.
Feature
Are Food Emulsifiers Associated With Increased Cancer Risk?
Food emulsifiers are among the most widespread food additives.
Feature
Democratic Lawmakers Press Pfizer on Chemotherapy Drug Shortages
The company, which said in May that it was working to assuage critical shortages of methotrexate, carboplatin and cisplatin, is being asked to...
Commentary
Unleashing Our Immune Response to Quash Cancer
“It’s astounding how devious cancer cells and tumor tissue can be.”
From the Journals
Belantamab Mafodotin Tops Daratumumab in Multiple Myeloma
The anti-BCMA monoclonal antibody conjugate outperformed daratumumab as a second-line option for relapsed or refractory multiple myeloma.
Feature
Young Myeloma Specialist Forges Ahead, Gives Back
“Manni” Mohyuddin, MD, reflects on patient needs, compassionate care, medical education, and recent advances in treating multiple myeloma.
Conference Coverage
New Multiple Myeloma Staging Systems Outperform the Standard
Retrospective study shows that the proposed new systems offer more refined risk classifications in stages of myeloma.
Conference Coverage
In Transplant-Ineligible Myeloma, This Frontline Tx Is Better
New study finds a top performer among “preferred” treatment combos for patients with multiple myeloma who can’t get stem cell transplants.
Conference Coverage
No Benefit to Salvage Transplant in R/R Multiple Myeloma
Fresh data confirm that a second transplant does not improve survival vs. standard two-drug regimen for relapsed myeloma.